000 01492 a2200421 4500
005 20250518013540.0
264 0 _c20200204
008 202002s 0 0 eng d
022 _a1473-4877
024 7 _a10.1080/03007995.2018.1560220
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aEmond, Bruno
245 0 0 _aReal-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans.
_h[electronic resource]
260 _bCurrent medical research and opinion
_c03 2019
300 _a407-416 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAntipsychotic Agents
_xadministration & dosage
650 0 4 _aDrug Administration Schedule
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aPaliperidone Palmitate
_xadministration & dosage
650 0 4 _aRetrospective Studies
650 0 4 _aSchizophrenia
_xdrug therapy
700 1 _aEl Khoury, Antoine C
700 1 _aPatel, Charmi
700 1 _aPilon, Dominic
700 1 _aMorrison, Laura
700 1 _aZhdanava, Maryia
700 1 _aLefebvre, Patrick
700 1 _aTandon, Neeta
700 1 _aJoshi, Kruti
773 0 _tCurrent medical research and opinion
_gvol. 35
_gno. 3
_gp. 407-416
856 4 0 _uhttps://doi.org/10.1080/03007995.2018.1560220
_zAvailable from publisher's website
999 _c29169583
_d29169583